NCT06617000View on ClinicalTrials.gov

A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

PHASE1RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
HCCHepatitis B Virus Related Hepatocellular CarcinomaHepatocellular Carcinoma
Interventions
BIOLOGICAL

SCG101

Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.

Trial Locations (7)

100020

RECRUITING

Beijing, Beijing

110000

RECRUITING

Shenyang, Shenyang

130000

RECRUITING

Changchun, Changchun

200000

RECRUITING

Shanghai, Shanghai

250000

RECRUITING

Ji'nan, Ji'nan

450003

RECRUITING

Zhengzhou, Zhengzhou

510000

RECRUITING

Guangzhou, Guangzhou

All Listed Sponsors
lead

SCG Cell Therapy Pte. Ltd.

INDUSTRY